172 related articles for article (PubMed ID: 22614986)
1. Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?
Burstein HJ; Piccart-Gebhart MJ; Perez EA; Hortobagyi GN; Wolmark N; Albain KS; Norton L; Winer EP; Hudis CA
J Clin Oncol; 2012 Jun; 30(18):2179-82. PubMed ID: 22614986
[No Abstract] [Full Text] [Related]
2. Cardiotoxicity debated for anthracyclines and trastuzumab in breast cancer.
Brower V
J Natl Cancer Inst; 2013 Jun; 105(12):835-6. PubMed ID: 23733910
[No Abstract] [Full Text] [Related]
3. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
Krop IE; Suter TM; Dang CT; Dirix L; Romieu G; Zamagni C; Citron ML; Campone M; Xu N; Smitt M; Gianni L
J Clin Oncol; 2015 Apr; 33(10):1136-42. PubMed ID: 25713436
[TBL] [Abstract][Full Text] [Related]
4. Is it safe to give anthracyclines concurrently with trastuzumab in neo-adjuvant or metastatic settings for HER2-positive breast cancer? A meta-analysis of randomized controlled trials.
Du F; Yuan P; Zhu W; Wang J; Ma F; Fan Y; Xu B
Med Oncol; 2014 Dec; 31(12):340. PubMed ID: 25416049
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
Rowan K
J Natl Cancer Inst; 2009 Apr; 101(7):448-9. PubMed ID: 19318626
[No Abstract] [Full Text] [Related]
6. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
Castrellon AB; Glück S
Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
[TBL] [Abstract][Full Text] [Related]
7. Ongoing debate: anthracyclines and adjuvant treatment of human epidermal growth factor receptor 2-positive breast cancer.
Mahesh S
J Clin Oncol; 2012 Dec; 30(35):4445-6; author reply 4446. PubMed ID: 23071231
[No Abstract] [Full Text] [Related]
8. Adjuvant anthracyclines: time for a change of heart?
O'Regan R
Oncology (Williston Park); 2011 Feb; 25(2):140, 142. PubMed ID: 21456385
[No Abstract] [Full Text] [Related]
9. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.
Bowles EJ; Wellman R; Feigelson HS; Onitilo AA; Freedman AN; Delate T; Allen LA; Nekhlyudov L; Goddard KA; Davis RL; Habel LA; Yood MU; McCarty C; Magid DJ; Wagner EH;
J Natl Cancer Inst; 2012 Sep; 104(17):1293-305. PubMed ID: 22949432
[TBL] [Abstract][Full Text] [Related]
10. [HER-2/neu positive breast cancer: how to prescribe adjuvant trastuzumab (Herceptin)?].
Belkacémi Y; Gligorov J; Mauriac L; Azria D
Bull Cancer; 2006 Oct; 93(10):991-9. PubMed ID: 17074658
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant treatment of HER2-positive breast cancer: winning efforts continue to improve HER2-positive patient outcome long-term.
Jankowitz RC; Brufsky AM
Breast Cancer Res; 2012 Apr; 14(2):308. PubMed ID: 22546039
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be?
Morris PG; Hudis CA
J Clin Oncol; 2010 Jul; 28(21):3407-10. PubMed ID: 20530269
[No Abstract] [Full Text] [Related]
13. Trastuzumab plus chemotherapy improves survival in early-stage HER2-positive breast cancer patients.
Oncology (Williston Park); 2005 Jun; 19(7):851, 862. PubMed ID: 16053034
[No Abstract] [Full Text] [Related]
14. Re: Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.
Magné N; Chargari C
Nat Clin Pract Oncol; 2008 Nov; 5(11):E1. PubMed ID: 18957967
[No Abstract] [Full Text] [Related]
15. [Retrospective analysis of trastuzumab treatment in 141 patients with Her-2 positive breast cancer].
Wang Y; Li JJ; DI GH; Lu JS; Wu J; Liu GY; Hu XC; Wang ZH; Yang WT; Shao ZM
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):864-7. PubMed ID: 21223695
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab before breast surgery: is concurrent administration with anthracycline-containing chemotherapy necessary?
Del Mastro L; Bighin C; Bini G; Giraudi S; Taveggia P; Levaggi A; Canavese G; Rescinito G; Pronzato P
Ann Oncol; 2010 Jun; 21(6):1376-1377. PubMed ID: 20430904
[No Abstract] [Full Text] [Related]
17. Adjuvant trastuzumab in HER2-positive breast cancer.
Slamon D; Eiermann W; Robert N; Pienkowski T; Martin M; Press M; Mackey J; Glaspy J; Chan A; Pawlicki M; Pinter T; Valero V; Liu MC; Sauter G; von Minckwitz G; Visco F; Bee V; Buyse M; Bendahmane B; Tabah-Fisch I; Lindsay MA; Riva A; Crown J;
N Engl J Med; 2011 Oct; 365(14):1273-83. PubMed ID: 21991949
[TBL] [Abstract][Full Text] [Related]
18. Can we abandon anthracyclines for early breast cancer patients?
Henderson IC
Oncology (Williston Park); 2011 Feb; 25(2):115-24, 127. PubMed ID: 21456382
[TBL] [Abstract][Full Text] [Related]
19. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
Slamon DJ; Leyland-Jones B; Shak S; Fuchs H; Paton V; Bajamonde A; Fleming T; Eiermann W; Wolter J; Pegram M; Baselga J; Norton L
N Engl J Med; 2001 Mar; 344(11):783-92. PubMed ID: 11248153
[TBL] [Abstract][Full Text] [Related]
20. HER2 testing in patients with breast cancer.
Dixon JM; Wilson V; Verrill M; Symmans WF
BMJ; 2012 Jun; 344():e3958. PubMed ID: 22689887
[No Abstract] [Full Text] [Related]
[Next] [New Search]